ScreenerHero

CTMXCytomX Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · cytomx.com
3.280USD-8.12%Mkt Cap: 714.71M $P/E: —

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platfo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap714.71M $
Enterprise Value392.31M $
Revenue (TTM)18.30M $
Gross Profit18.30M $
Net Income (TTM)-17.37M $
Revenue/Share0.1000 USD
Last Price3.280 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.95
PEG—
EV/EBITDA-4.55
EV/Revenue21.43
P/S39.17
P/B2.37
EPS (TTM)-0.53
EPS (Forward)-0.47
52W Range
1.88522% of range8.210
52W High8.210 USD
52W Low1.885 USD
Profitability
Gross Margin100.00%
Oper. Margin-1677.08%
EBITDA Margin0.00%
Profit Margin-22.79%
ROE-17.54%
ROA-11.46%
Growth
Revenue Growth-92.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-75.59M $
CapEx (TTM)220.00K $
FCF Margin-410.93%
FCF Yield-10.52%
Net Debt-324.58M $
Net Debt/EBITDA3.76
Balance Sheet
Debt/Equity0.04
Current Ratio9.36
Quick Ratio9.26
Book Value/Sh1.386 USD
Cash/Share1.516 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.25 USD
Upside (mean)+273.5%
Target Range6.000 USD – 16.00 USD
$6.000+273.5% to mean$16.00
# Analysts8
Ownership
Shares Out.217.90M
Float179.76M
Insiders0.57%
Institutions103.79%
Short Interest
Short Ratio9.9d
Short % Float18.28%
Short % Out.16.11%
Shares Short35.11M
Short (prev mo.)35.57M
Technical
SMA 503.394 (-3.4%)
SMA 2004.186 (-21.6%)
Beta2.14
S&P 52W Chg18.16%
Avg Vol (30d)2.76M
Avg Vol (10d)2.37M
Technical Indicators
RSI (14)44.6
MACD-0.0061
MACD Signal-0.0184
MACD Hist.+0.0122
BB Upper3.575 USD
BB Middle3.333 USD
BB Lower3.090 USD
BB Width14.57%
ATR (14)0.1679 USD
Vol Ratio (20d)1.34x